Chief Medical Officer / SVP Clinical Development (m/f/d)

About SJP Biotec

SJP Biotec GmbH is a clinical-stage precision oncology company pioneering a first-in-class Selective Translation Regulatory Inhibitor (STRI) platform powered to overcome treatment resistance in refractory cancers. Founded in 2024, SJP targets RAS-driven, hormone-receptor-positive, and immune-refractory tumors with a novel pipeline of small molecules developed in our lab and ready to proceed with regulatory-grade trials.

Backed by a Scientific Advisory Board that includes world-leading authorities in RAS and breast cancer biology, and immuno-oncology, SJP has established clinical partnerships with leading medical centers world-wide including UCSF, NCI, MD Anderson, Baylor College of Medicine, MSKCC, and McGill, to name a few.

Chief Medical Officer / SVP Clinical Development (m/f/d)

SJP Biotec GmbH | Precision Oncology | RAS-MAPK & Translation Biology | Switzerland | Remote-Flexible

The Opportunity
This is a stimulating and unique opportunity to join a scientifically exceptional, capital-efficient biotech company doing groundbreaking work at a pivotal inflection point. The CMO/SVP of Clinical Development will serve as the company's most senior clinical leader, responsible for designing and executing a multi-indication clinical development strategy across one of the most compelling areas in the current oncology drug development field - RAS/eIF4A/translation-pathway inhibition.

CLTRD1_DE